(Q37772816)

22 August 2017

1 reference

title

Small cell lung cancer: past, present, and future (English)

1 reference

22 August 2017

1 reference

Estelamari Rodriguez

1

1 reference

PubMed ID

20632219

22 August 2017

Rogerio C Lilenbaum

series ordinal

2

1 reference

22 August 2017

1 September 2010

1 reference

22 August 2017

Current Oncology Reports

1 reference

22 August 2017

12

1 reference

22 August 2017

5

1 reference

22 August 2017

327-334

1 reference

https://scigraph.springernature.com/pub.10.1007/s11912-010-0120-5

22 August 2017

0 references

cites work

A meta-analysis of thoracic radiotherapy for small-cell lung cancer

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11912-010-0120-5

Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer

21 January 2018

1 reference

12 December 2020

Maintenance daily oral etoposide versus no further therapy following induction chemotherapy with etoposide plus ifosfamide plus cisplatin in extensive small-cell lung cancer: a Hoosier Oncology Group randomized study

1 reference

12 December 2020

Phase II study of cisplatin plus etoposide and bevacizumab for previously untreated, extensive-stage small-cell lung cancer: Eastern Cooperative Oncology Group Study E3501

1 reference

12 December 2020

A phase II trial of imatinib (ST1571) in patients with c-kit expressing relapsed small-cell lung cancer: a CALGB and NCCTG study.

1 reference

12 December 2020

Randomized comparison of etoposide-cisplatin vs. etoposide-carboplatin and irradiation in small-cell lung cancer. A Hellenic Co-operative Oncology Group study

1 reference

12 December 2020

Expression of bcl-2 in small cell lung carcinoma cells.

1 reference

12 December 2020

Cyclophosphamide, doxorubicin, and vincristine in etoposide- and cisplatin-resistant small cell lung cancer.

1 reference

12 December 2020

Cyclophosphamide, doxorubicin and vincristine with amphotericin B in sonicated liposomes as salvage therapy for small cell lung cancer

1 reference

12 December 2020

A systematic review of the role of etoposide and cisplatin in the chemotherapy of small cell lung cancer with methodology assessment and meta-analysis

1 reference

12 December 2020

Expanding circle of inhibition: small-molecule inhibitors of Bcl-2 as anticancer cell and antiangiogenic agents

1 reference

12 December 2020

Phase II study of vandetanib or placebo in small-cell lung cancer patients after complete or partial response to induction chemotherapy with or without radiation therapy: National Cancer Institute of Canada Clinical Trials Group Study BR.20

1 reference

12 December 2020

Imatinib mesylate (STI571) enhances amrubicin-induced cytotoxic activity through inhibition of the phosphatidylinositol 3-kinase/Akt pathway in small cell lung cancer cells

1 reference

12 December 2020

The value of prognostic factors in small cell lung cancer: results from a randomised multicenter study with minimum 5 year follow-up

1 reference

12 December 2020

Phase II trial of amrubicin for treatment of refractory or relapsed small-cell lung cancer: Thoracic Oncology Research Group Study 0301.

1 reference

12 December 2020

Prophylactic cranial irradiation in extensive small-cell lung cancer

1 reference

12 December 2020

Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124.

1 reference

12 December 2020

Phase III study of pemetrexed plus carboplatin compared with etoposide plus carboplatin in chemotherapy-naive patients with extensive-stage small-cell lung cancer

1 reference

12 December 2020

Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group

1 reference

12 December 2020

Report on the IASLC Le Havre Workshop on combined modality treatment in small cell lung cancer

1 reference

12 December 2020

Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database.

1 reference

12 December 2020

Topotecan versus observation after cisplatin plus etoposide in extensive-stage small-cell lung cancer: E7593--a phase III trial of the Eastern Cooperative Oncology Group

1 reference

12 December 2020

Is there a case for cisplatin in the treatment of small-cell lung cancer? A meta-analysis of randomized trials of a cisplatin-containing regimen versus a regimen without this alkylating agent

1 reference

12 December 2020

A prospective randomized trial to determine the benefit of surgical resection of residual disease following response of small cell lung cancer to combination chemotherapy

1 reference

12 December 2020

Alkylating agents in bronchogenic carcinoma

1 reference

12 December 2020

Twenty years of phase III trials for patients with extensive-stage small-cell lung cancer: perceptible progress

1 reference

12 December 2020

Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer

1 reference

12 December 2020

Phase I study to determine the maximum-tolerated dose of radiation in standard daily and hyperfractionated-accelerated twice-daily radiation schedules with concurrent chemotherapy for limited-stage small-cell lung cancer

1 reference

12 December 2020

The International Association for the Study of Lung Cancer lung cancer staging project: proposals regarding the clinical staging of small cell lung cancer in the forthcoming (seventh) edition of the tumor, node, metastasis classification for lung ca

1 reference

12 December 2020

Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer

1 reference

12 December 2020

Imatinib mesylate lacks activity in small cell lung carcinoma expressing c-kit protein: a phase II clinical trial

1 reference

12 December 2020

A randomized, phase II trial of two dose levels of temsirolimus (CCI-779) in patients with extensive-stage small-cell lung cancer who have responding or stable disease after induction chemotherapy: a trial of the Eastern Cooperative Oncology Group (

1 reference

12 December 2020

Phase II study of picoplatin as second-line therapy for patients with small-cell lung cancer

1 reference

12 December 2020

Randomized phase II trial comparing amrubicin with topotecan in patients with previously treated small-cell lung cancer: North Japan Lung Cancer Study Group Trial 0402.

1 reference

12 December 2020

VP-16 and cisplatin as first-line therapy for small-cell lung cancer

1 reference

12 December 2020

Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer

1 reference

12 December 2020

Randomized Trial of Cyclophosphamide, Doxorubicin, and Vincristine Versus Cisplatin and Etoposide Versus Alternation of These Regimens in Small-Cell Lung Cancer

1 reference

12 December 2020

Phase I-II study of amrubicin and cisplatin in previously untreated patients with extensive-stage small-cell lung cancer

1 reference

12 December 2020

Follow-up of cognitive functioning in patients with small cell lung cancer

1 reference

12 December 2020

Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide

1 reference

12 December 2020

Gefitinib in patients with chemo-sensitive and chemo-refractory relapsed small cell cancers: a Hoosier Oncology Group phase II trial

1 reference

12 December 2020

Does thoracic irradiation improve survival and local control in limited-stage small-cell carcinoma of the lung? A meta-analysis

1 reference

12 December 2020

Randomized phase III intergroup trial of etoposide and cisplatin with or without paclitaxel and granulocyte colony-stimulating factor in patients with extensive-stage small-cell lung cancer: Cancer and Leukemia Group B Trial 9732.

1 reference

12 December 2020

Paraneoplastic syndromes associated with small cell lung cancer

1 reference

12 December 2020

Maintenance chemotherapy for small cell lung cancer: a critical review of the literature

1 reference

12 December 2020

Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and

1 reference

12 December 2020

Randomized phase II Study of carboplatin and etoposide with or without the bcl-2 antisense oligonucleotide oblimersen for extensive-stage small-cell lung cancer: CALGB 30103.

1 reference

12 December 2020

10.1007/S11912-010-0120-5

Identifiers

DOI

1 reference

22 August 2017

1 reference

PubMed ID

20632219